Stocktwits on MSN
SLS stock breaches $5 level after over 3 years: Retail now eyes buyout for as much as $25B
SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid ...
SELLAS Life Sciences Group climbs higher after a premarket drop, reversing course as investors seem to react to new trial‑related updates.
$SLS insiders have traded $SLS stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales. Here’s a ...
The average one-year price target for SELLAS Life Sciences Group (NASDAQ:SLS) has been revised to 7.14 / share. This is an increase of 16.67% from the prior estimate of 6.12 dated October 31, 2023.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback